Back to Search
Start Over
Retrospective survey of compounded medications for children in Japan.
- Source :
-
European Journal of Pharmaceutics & Biopharmaceutics . Oct2020, Vol. 155, p122-127. 6p. - Publication Year :
- 2020
-
Abstract
- Compounding of medications, such as crushing tablets and dispersing the contents of capsules, is a common practice in pharmacies and hospitals worldwide and is often done to provide age-appropriate formulations for oral use in pediatric patients. In the present study, a retrospective, descriptive, questionnaire-based survey was conducted to clarify the current status of drug compounding for pediatric patients in Japan. An electronic questionnaire was distributed to 740 hospitals in Japan with pediatric beds, and 208 (28.1%) of these hospitals responded. The total instances of compounding numbered 14,864 (9.6% of the total pediatric oral prescriptions) and comprised 266 active pharmaceutical ingredients (APIs), one-third of which (98 APIs) were compounded even though flexible dosage forms were available. The three most frequently compounded drugs were dantrolene sodium capsules (1152 prescriptions), ramelteon tablets (726 prescriptions), and hydrocortisone tablets (652 prescriptions), all of which were prescribed and administered in powder form. Although compounding of medications frequently varied by the patients' age, steroids such as prednisolone, dexamethasone, and hydrocortisone were commonly compounded in all age groups. To ensure the quality and safety of these compounded medications, developing a standard protocol for compounding methods is urgently needed in Japan. [ABSTRACT FROM AUTHOR]
- Subjects :
- *CHILDREN'S hospitals
*DOSAGE forms of drugs
*DRUGS
*HOSPITAL pharmacies
*AGE groups
Subjects
Details
- Language :
- English
- ISSN :
- 09396411
- Volume :
- 155
- Database :
- Academic Search Index
- Journal :
- European Journal of Pharmaceutics & Biopharmaceutics
- Publication Type :
- Academic Journal
- Accession number :
- 145679622
- Full Text :
- https://doi.org/10.1016/j.ejpb.2020.08.016